Targets › TMEM173
3 programs from 3 companies in 14 trials: 6 Phase 1, 5 Phase 2, 3 Phase 3; Oncology; next expected readout Dec 2026.
Key innate immune signaling adapter that promotes the production of type I interferon (IFN-alpha and IFN-beta) in response to the presence of DNA from bacteria and viruses in the cytosol. Innate immune response is triggered by non-CpG double-stranded DNA from viruses and bacteria delivered to the cytoplasm, which induces production of cyclic dinucleotides that bind and activate STING1: STING1 recognizes and binds…. (UniProt, Q86WV6)
Open in Phaseline: the race on TMEM173, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Pfizer | PF-08634404 Stimulator of Interferon genes (STING) agonist | TMEM173 | Phase 3 | Advanced Non-Small Cell Lung Cancer; Endometrial Neoplasms; Intestinal Neoplasms; Small Cell Lung Cancer … | Oct 2027 |
| RenJi Hospital | Iparomlimab and Tuvonralimab (QL1706) STING agonist | TMEM173 | Phase 2 | HR-positive/HER2-negative Breast Cancer | Dec 2026 |
| Memorial Sloan Kettering Cancer Center | CRD3874-SI STING agonist | TMEM173 | Phase 1 | Acute Myeloid Leukemia; Sarcoma | Jun 2028 |
Advanced Non-Small Cell Lung Cancer (1) Endometrial Neoplasms (1) Intestinal Neoplasms (1) Small Cell Lung Cancer (1) Carcinoma (1) Small Cell Lung Cancer (SCLC) (1) Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma (1) Carcinoma, Hepatocellular (1) Carcinoma, Renal Cell (1) Urothelial Cancer (1) Advanced/Metastatic Non-Small Cell Lung Cancer (1) Acute Myeloid Leukemia (1)
mixed (2), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.